SciSparc Ltd. announced that the first patient has been enrolled in the Company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment of children with autism spectrum disorder (?ASD?) between the ages of 5 and 18. Autism, also referred to as autism spectrum disorder, is one of the most common developmental disabilities globally with a prevalence of approximately one in 36 children, according to estimates from the Centers for Disease Control and Prevention?s Autism and Developmental Disabilities Monitoring (ADDM) Network and is accompanied by an unmet need for efficient and safe treatments. The Company's goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.

About the ASD trial: The double-blind, randomized and placebo-controlled study will be performed using SciSparc's proprietary SCI-210, a combination of cannabidiol (CBD) and CannAmide? (SciSparc?s Palmitoylethanolamide), which is designed to alleviate ASD symptoms. SciSparc will enroll 60 subjects between the ages of 5 and 18, for 20 weeks, with the purpose of assessing how SCI-210 therapy compares to standard CBD treatment in managing symptoms of ASD. The trial has three primary efficacy metrics: the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement (CGI-I) performed by a clinician; and the effective therapeutic dose.

The trial was designed in consultation with the National Autism Research Center, the leading research center for autism in Israel. ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.